Last reviewed · How we verify
Intravenous Omeprazole
Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis.
At a glance
| Generic name | Intravenous Omeprazole |
|---|---|
| Also known as | iv losec |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The intravenous formulation provides rapid onset of action for acute acid suppression in patients unable to take oral medication.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Stress ulcer prophylaxis
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia
- Vitamin B12 deficiency
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
- High Dose Oral Omeprazole in High Risk UGIB (NA)
- A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis (PHASE1)
- Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1 (NA)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: